GnRH Agonist-only Trigger, Compared to Dual Trigger, Reduces Oocyte Retrieval Rate in High Responders Without Affecting Cumulative Live Birth Rate

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Sep 4

PMID 39229374

Authors

Yu Wang

Yu-Chiao Yi

Hwa-Fen Guu

Ya-Fang Chen

Hsiao-Fan Kung

Jui-Chun Chang

Li-Yu Chen

Shih-Ting Chuan

Ming-Jer Chen

Affiliations

Soon will be listed here.

Abstract

Introduction: This study compared, in high responders undergoing IVF treatment, GnRH agonist-only trigger and dual trigger on oocyte retrieval rate and cumulative live birth rate (LBR). The aim was to determine if the GnRH agonist-only triggers had provided outcomes comparable to dual trigger, while minimizing the risk of ovarian hyperstimulation syndrome (OHSS).

Materials And Methods: A retrospective, matched case-control study was conducted at Taichung Veterans General Hospital, Taiwan, including women who underwent IVF/ICSI between January 1, 2014, and December 31, 2022. Inclusion criteria were: GnRH antagonist protocol and estrogen level >3,000 pg/ml on trigger day. Exclusion criteria were: immune/metabolic diseases, donated oocytes, and mixed stimulation cycles. Propensity score matching was applied to balance age, AMH level, and oocyte number between the GnRH agonist-only and dual trigger groups. Outcomes were analyzed for patients who had complete treatment cycles, focusing on oocyte retrieval rate and cumulative LBR.

Results: We analyzed 116 cycles in the agonist-only group, and 232 cycles in the dual trigger group. No inter-group difference was found in their age, BMI, and AMH levels. The dual trigger group had a higher oocyte retrieval rate (93% vs. 80%; p <0.05), while fertilization rates, blastocyst formation rates, and cumulative LBR were comparable. Notably, no OHSS cases had been reported in the GnRH agonist-only group, compared with 7 cases in the dual trigger group.

Conclusion: GnRH agonist-only triggers resulted in a lower oocyte retrieval rate compared to dual triggers but did not significantly affect cumulative LBR in high responders. This approach effectively reduces OHSS risk without compromising pregnancy outcomes, making it a preferable option in freeze-all strategies, despite a longer oocyte pick-up duration and a medium cost. GnRH agonist-only trigger, however, may not be suitable for fresh embryo transfers or patients with low serum LH levels on trigger day.

References

Humaidan P, Alsbjerg B . GnRHa trigger for final oocyte maturation: is HCG trigger history?. Reprod Biomed Online. 2014; 29(3):274-80. DOI: 10.1016/j.rbmo.2014.05.008. View

Zelinski-Wooten M, Hutchison J, Hess D, Wolf D, Stouffer R . Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod. 1995; 10(7):1658-66. DOI: 10.1093/oxfordjournals.humrep.a136151. View

Jones B, Al-Chami A, Gonzalez X, Arshad F, Green J, Bracewell-Milnes T . Is oocyte maturity influenced by ovulation trigger type in oocyte donation cycles?. Hum Fertil (Camb). 2019; 24(5):360-366. DOI: 10.1080/14647273.2019.1671614. View

Alvarez C, Marti-Bonmati L, Novella-Maestre E, Sanz R, Gomez R, Fernandez-Sanchez M . Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007; 92(8):2931-7. DOI: 10.1210/jc.2007-0409. View

Castillo J, Humaidan P, Bernabeu R . Pharmaceutical options for triggering of final oocyte maturation in ART. Biomed Res Int. 2014; 2014:580171. PMC: 4123594. DOI: 10.1155/2014/580171. View

Castillo J, Garcia-Velasco J, Humaidan P . Empty follicle syndrome after GnRHa triggering versus hCG triggering in COS. J Assist Reprod Genet. 2012; 29(3):249-53. PMC: 3288136. DOI: 10.1007/s10815-011-9704-8. View

Griesinger G, Kolibianakis E, Papanikolaou E, Diedrich K, VAN Steirteghem A, Devroey P . Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil Steril. 2007; 88(3):616-21. DOI: 10.1016/j.fertnstert.2006.12.006. View

Maged A, Ragab M, Shohayeb A, Saber W, Ekladious S, Hussein E . Comparative study between single versus dual trigger for poor responders in GnRH-antagonist ICSI cycles: A randomized controlled study. Int J Gynaecol Obstet. 2020; 152(3):395-400. DOI: 10.1002/ijgo.13405. View

Seyhan A, Ata B, Polat M, Son W, Yarali H, Dahan M . Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod. 2013; 28(9):2522-8. DOI: 10.1093/humrep/det124. View

10.

Soares S, Gomez R, Simon C, Garcia-Velasco J, Pellicer A . Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008; 14(4):321-33. DOI: 10.1093/humupd/dmn008. View

11.

Delvigne A, Rozenberg S . Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod. 2001; 16(12):2491-5. DOI: 10.1093/humrep/16.12.2491. View

12.

Humaidan P, Kol S, Papanikolaou E . GnRH agonist for triggering of final oocyte maturation: time for a change of practice?. Hum Reprod Update. 2011; 17(4):510-24. DOI: 10.1093/humupd/dmr008. View

13.

ONeill K, Senapati S, Maina I, Gracia C, Dokras A . GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. J Assist Reprod Genet. 2016; 33(9):1175-84. PMC: 5010813. DOI: 10.1007/s10815-016-0755-8. View

14.

Kolibianakis E, Schultze-Mosgau A, Schroer A, VAN Steirteghem A, Devroey P, Diedrich K . A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod. 2005; 20(10):2887-92. DOI: 10.1093/humrep/dei150. View

15.

. Ovarian hyperstimulation syndrome. Fertil Steril. 2008; 90(5 Suppl):S188-93. DOI: 10.1016/j.fertnstert.2008.08.034. View

16.

Lin M, Wu F, Hwu Y, Lee R, Li R, Li S . Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve. Reprod Biol Endocrinol. 2019; 17(1):7. PMC: 6320621. DOI: 10.1186/s12958-018-0451-x. View

17.

Chern C, Li J, Tsui K, Wang P, Wen Z, Lin L . Dual-trigger improves the outcomes of in vitro fertilization cycles in older patients with diminished ovarian reserve: A retrospective cohort study. PLoS One. 2020; 15(7):e0235707. PMC: 7337315. DOI: 10.1371/journal.pone.0235707. View

18.

Maslow B, Guarnaccia M, Stefanacci C, Ramirez L, Klein J . The use of GnRH-agonist trigger for the final maturation of oocytes in normal and low responders undergoing planned oocyte cryopreservation. Hum Reprod. 2020; 35(5):1054-1060. DOI: 10.1093/humrep/deaa042. View

19.

Hoff J, Quigley M, Yen S . Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab. 1983; 57(4):792-6. DOI: 10.1210/jcem-57-4-792. View

20.

Alyasin A, Mehdinejadiani S, Ghasemi M . GnRH agonist trigger versus hCG trigger in GnRH antagonist in IVF/ICSI cycles: A review article. Int J Reprod Biomed. 2016; 14(9):557-566. PMC: 5054292. View